Superworth

DENTSPLY SIRONA XRAY

Medical - Instruments & Supplies, Healthcare
$9.43
−0.74%
Market cap
$1.9B
PE
n/m
a loss over the last year
Forward PE
n/m
not a meaningful number
Price to sales
0.5×
EV/EBIT
n/m
a loss over the last year
Revenue, 12 months
$3.6B
−1% on a year ago
Net margin
−15.0%
Free cash flow yield
7.6%

DENTSPLY SIRONA trades at 0.5× sales. Its trailing earnings are negative, so it has no PE. Revenue was $3.6B over the last twelve months, down 1% on a year earlier with a −15% net margin.

Charts

Financials

Income statement for XRAY, by quarter
Income statementQ3 FY23Q4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
$947M+0%$1B+3%$953M−3%$984M−4%$951M+0%$905M−11%$879M−8%$936M−5%$904M−5%$961M+6%$880M+0%$898M−4%
Cost of revenue$452M+3%$490M+5%$447M−3%$473M−1%$456M+1%$459M−6%$413M−8%$446M−6%$463M+2%$518M+13%$453M+10%$405M−9%
Gross profit$495M−3%$522M+1%$506M−3%$511M−7%$495M+0%$446M−15%$466M−8%$490M−4%$441M−11%$443M−1%$427M−8%$493M+1%
R&D$46M+12%$43M+0%$42M−9%$41M−16%$40M−13%$42M−2%$36M−14%$37M−10%$37M−8%$40M−5%$44M+22%$45M+22%
SG&A$372M−7%$409M+2%$415M−0%$399M−4%$390M+5%$401M−2%$358M−14%$342M−14%$355M−9%$383M−5%$351M−2%$364M+6%
−$236M−81%$73M+12%$42M$50M−38%−$462M+96%−$509M$63M+50%−$128M−$218M−53%−$139M−73%−$35M$82M
Interest expense$19M+36%$20M+5%$18M−10%$17M−23%$18M−5%$16M−20%$19M+6%$24M+41%$23M+28%$22M+38%$24M+26%$22M−8%
Pre-tax income−$250M−80%$57M+613%$31M$34M−26%−$478M+91%−$523M$44M+42%−$153M−$230M−52%−$147M−72%−$42M$72M
$16M−$15M$14M$38M$17M+6%−$95M+533%$25M+79%−$109M$198M+1065%−$2M−98%−$32M$36M
Net income−$266M−75%$67M$18M−$4M−$494M+86%−$430M$20M+11%−$45M+1025%−$427M−14%−$146M−66%−$10M$37M
−$1.25−75%$0.32$0.09−$0.02−$2.46+97%−$2.16$0.10+11%−$0.22+1000%−$2.14−13%−$0.73−66%−$0.05$0.18
211.8M−1%209.9M−3%208.5M−3%205.6M−4%201M−5%198.7M−5%199.8M−4%199.3M−3%199.5M−1%199.7M+1%199.9M+0%200.5M+1%

EPS, diluted: 10 periods, Q4 FY08 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: 14 periods, Q4 FY08 to Q4 FY23: share-days: the 12-month average less the 9-month, weighted by days. 4 periods, Q4 FY17 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Medical - Instruments & Supplies nearest DENTSPLY SIRONA's size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
XRAYDENTSPLY SIRONA$1.9Bn/m34.2×0.5×−1%−15.0%
LMATLemaitre Vascular$1.9B29.6×42.0×7.4×+12%25.0%
INSPInspire Medical Systems$2.1B15.4×58.0×2.3×+4%15.0%
UFPTUFP Technologies$2.3B31.9×25.6×3.6×+7%11.4%
EYENational Vision$1.5B30.6×53.3×0.7×+8%2.5%
CDRECadre$1.3B37.0×35.8×1.9×+20%5.3%
BVSBioventus$1.3B19.4×27.2×2.2×+3%9.4%
ATRCAtriCure$3B281×58.4×5.3×+14%1.9%
STAAStaar Surgical$1.1B323×143×3.3×+51%1.1%
WRBYWarby Parker$3.2B370×366×3.5×+11%0.8%
IRMDIradimed$1.1B47.9×41.4×12.7×+11%26.7%
Peer median$1.7B34.4×47.7×3.4×+11%7.3%

Investors who own it

Investors we follow who held DENTSPLY SIRONA at the end of Jun 30, 2026, from their 13F filings.

More on DENTSPLY SIRONA

Each number over time

Where it ranks

Its groups

About

Industry
Medical - Instruments & Supplies
Sector
Healthcare

Valuation data, not investment advice. Prices as of .